ImClone Opts Out Of Anti-VEGF Deal With UCB To Focus On Proprietary Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
ImClone will develop IMC-1121B after the biologic demonstrated promising clinical activity in Phase I, firm says.
You may also be interested in...
ImClone Metastatic Breast Cancer Candidate Moves Into Phase III In Third Quarter
Firm sets progression-free survival as primary endpoint for 1,100-patient trial.
ImClone Metastatic Breast Cancer Candidate Moves Into Phase III In Third Quarter
Firm sets progression-free survival as primary endpoint for 1,100-patient trial.
ImClone VEGF Development Program Expands, Gains Insurance With UCB Deal
Fifty-fifty partnership will co-develop UCB’s CDP-791 for use in solid tumors while ImClone continues work on in-house oncologic IMC-1121B.